South Africa’s high tuberculosis (TB) burden and the high HIV incidence results in significant morbidity and mortality. The diagnosis of TB in HIV co-infected individuals has been complicated by paucibacillary infection leading to sputum AFB negative TB.
Diagnosing TB can be challenging in HIV positive individuals as many have paucibacillary pulmonary disease. Development of new diagnostic techniques are important as well as the development of shorter treatment regimens.
A focus of the research activity of CHRU has been to establish alternative diagnostic methods, as well as the initiation of ART in patients presenting tuberculosis (TB).
CHRU also aims to:
- Impact on the treatment of HIV and TB including M/XDR TB by evaluating novel treatment strategies for HIV and co-morbidities, including new drugs for HIV treatment
- Improve the diagnosis and treatment of tuberculosis, including those co-infected with HIV
- Transform tuberculosis therapeutics by optimizing regimens both to prevent and treat.
CHRU’s research activities around TB are integrated with South Africa’s National TB Program (NTP).
The main clinical trials in TB that are currently underway are listed below: